跳至主要内容
临床试验/ISRCTN15768745
ISRCTN15768745暂停Unknown

A cluster-randomised 12-month, parallel arm, superiority trial of a multifaceted intervention to promote child VaccInation and linKage to sociAl protection Schemes (VIKAS) versus usual services on vaccination uptake among children 12 - 23 months

Canadian Institutes of Health Research0 个研究点目标入组 7,810 人开始时间: 2024年6月26日最近更新:
适应症

试验速览

阶段
Unknown
状态
暂停
入组人数
7,810

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Communities:
  • 1.1. Located in a catchment area of a health sub-centre assigned to the intervention group,
  • 1.2. Designated as possible missed community (low immunisation area), and
  • 1.3. Consent is received from community gatekeepers (local elected officials with territorial responsibility, such as the Pradhan (mayor)).
  • 2. All adult (>18 years of age) participants in communities selected to receive the intervention will be eligible to participate
  • 3. All frontline health workers in the intervention group with territorial responsibility for a community selected to receive the interventions will be included in the field interventions.
  • 4. Participants in the baseline and end line cross-sectional household surveys are primary caregivers (usually mothers) and other adult (over age 18 years ) family members of immunisation-age (0 to 23 months) children. Participants are eligible for inclusion in the household surveys if they reside in a study cluster (rural health sub-centre) catchment area and in an immunisation microplan area designated as a possible low immunisation area, and provide written informed consent. We will exclude those not able to understand and speak Hindi or Urdu.

排除标准

  • 1. Participation in Interventions: None.
  • 2. Participation in data collection: We will exclude those not able to understand and speak Hindi or Urdu. Based on our experience, in this district, this criterion would result in exclusion of less than 1% of respondents.

研究者

相似试验

进行中(未招募)
1 期
Comparison of Ozurdex versus Lucentis in the treatment of BranchRetinal Vein Occlusion.Macula oedema secondary to branch retinal vein occlusion.MedDRA version: 14.0Level: PTClassification code 10025415Term: Macular oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: PTClassification code 10038907Term: Retinal vein occlusionSystem Organ Class: 10015919 - Eye disorders
EUCTR2010-023900-29-ESAllergan Pharmaceuticals Ireland307
进行中(未招募)
1 期
A 12-Month, Multicentre, Randomised, Parallel Group Study to Comparethe Efficacy and Safety of Ozurdex Versus Lucentis in Patients withBranch Retinal Vein OcclusionMacula oedema secondary to branch retinal vein occlusionMedDRA version: 14.1Level: PTClassification code 10025415Term: Macular oedemaSystem Organ Class: 10015919 - Eye disorders
EUCTR2010-023900-29-ITALLERGAN PHARMACEUTICALS IRELAND307
进行中(未招募)
1 期
Comparison of Ozurdex versus Lucentis in the treatment of Branch Retinal Vein Occlusio
EUCTR2010-023900-29-GBAllergan Pharmaceuticals Ireland307
进行中(未招募)
不适用
Comparison of Ozurdex versus Lucentis in the treatment of Branch Retinal Vein Occlusio
EUCTR2010-023900-29-DEAllergan Pharmaceuticals Ireland308
进行中(未招募)
1 期
Study to assess the effect of AZD3241 in Multiple System AtrophyMultiple system atrophy (MSA)MedDRA version: 18.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2014-004902-13-SEAstraZeneca AB64
A cluster-randomised trial of a multifaceted... | 临床试验